June 3 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

A landmark international study that pooled brain scans and memory tests from thousands of adults has shed new light on how ...

Human herpesviruses comprise the alpha, beta, and gamma subfamilies and are a widely prevalent group of DNA-enveloped viruses, capable of establishing lifelong latent infections in humans and causing ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The research was the first to use neuroimaging to study the brains of children with avoidant/restrictive food intake disorder The study into avoidant/restrictive food intake disorder in children was ...